Answer
There is some evidence that glucocorticoids can down-regulate subtype 2 somatostatin receptors (SSTR2), so repeated high doses should be avoided as a precaution during Lutathera (lutetium (177Lu) oxodotreotide) treatment.
Sources for this answer
- Lutathera 370 MBq/mL solution for infusionNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 8Document updated
Sources checked